Literature DB >> 16817197

Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian.

Andrea Carmine Belin1, Marie Westerlund, Olof Sydow, Karin Lundströmer, Anna Håkansson, Hans Nissbrandt, Lars Olson, Dagmar Galter.   

Abstract

Specific variants of Leucine-rich repeat kinase 2 (LRRK2) have been shown to associate with Parkinson's disease (PD). Several mutations have been found in PD populations from different parts of the world. We investigated the occurrence of three mutations (R1441G/C/H, G2019S, and I2020T) in our Swedish case-control material and identified four carriers of the G2019S mutation in 284 PD cases and 1 95-year-old carrier in 305 controls. The other two variants were absent in our material. We conclude that the LRRK2 G2019S mutation constitutes a significant factor for PD in the Swedish population and that it is not completely penetrant.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16817197     DOI: 10.1002/mds.21016

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  12 in total

Review 1.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

Review 2.  Gene-environment interactions: key to unraveling the mystery of Parkinson's disease.

Authors:  Hui-Ming Gao; Jau-Shyong Hong
Journal:  Prog Neurobiol       Date:  2011-03-23       Impact factor: 11.685

Review 3.  Parkinson's disease: Exit toxins, enter genetics.

Authors:  Marie Westerlund; Barry Hoffer; Lars Olson
Journal:  Prog Neurobiol       Date:  2009-11-17       Impact factor: 11.685

4.  Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.

Authors:  Min Liu; Samantha A Bender; Gregory D Cuny; Woody Sherman; Marcie Glicksman; Soumya S Ray
Journal:  Biochemistry       Date:  2013-03-01       Impact factor: 3.162

5.  A prognostic view on the application of individualized genomics in Parkinson's disease.

Authors:  Owen A Ross
Journal:  Curr Genet Med Rep       Date:  2013-01-12

Review 6.  LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease.

Authors:  Vincenzo Bonifati
Journal:  Neurochem Res       Date:  2007-04-18       Impact factor: 3.996

7.  Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.

Authors:  R Nandhagopal; E Mak; M Schulzer; J McKenzie; S McCormick; V Sossi; T J Ruth; A Strongosky; M J Farrer; Z K Wszolek; A J Stoessl
Journal:  Neurology       Date:  2008-11-25       Impact factor: 9.910

Review 8.  Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.

Authors:  Payal N Gandhi; Shu G Chen; Amy L Wilson-Delfosse
Journal:  J Neurosci Res       Date:  2009-05-01       Impact factor: 4.164

Review 9.  Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.

Authors:  Karen Nuytemans; Jessie Theuns; Marc Cruts; Christine Van Broeckhoven
Journal:  Hum Mutat       Date:  2010-07       Impact factor: 4.878

10.  Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden.

Authors:  Caroline Ran; Lovisa Brodin; Lars Forsgren; Marie Westerlund; Mehrafarin Ramezani; Sandra Gellhaar; Fengqing Xiang; Camilla Fardell; Hans Nissbrandt; Peter Söderkvist; Andreas Puschmann; Emil Ygland; Lars Olson; Thomas Willows; Anders Johansson; Olof Sydow; Karin Wirdefeldt; Dagmar Galter; Per Svenningsson; Andrea Carmine Belin
Journal:  Neurobiol Aging       Date:  2016-05-03       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.